Evidence map›Paper›PMID 30559143›Full record

ArticleJournal of the American Society of Nephrology : JASN2019

Projecting ESRD Incidence and Prevalence in the United States through 2030.

Keith P McCullough, Hal Morgenstern, Rajiv Saran, William H Herman, Bruce M Robinson

Open access · bronzeAbstract read
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 173 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
173citing papers in PubMed, 6 pooled it
30.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

173 citing papers in PubMed, 6 syntheses or guidelines pooled it, 345 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Antihypertensive treatment for kidney transplant recipients.The Cochrane database of systematic reviews · 2024
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Predicting the Future Burden of Renal Replacement Therapy in Türkiye Using National Registry Data and Comparative Modeling Approaches.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026
    Article
  18. Review
  19. Medication adherence, health outcomes, and perceived social performance in Black Americans receiving hemodialysis.Health psychology : official journal of the Division of Health Psychology, American Psychological Association · 2026
    Article
  20. Article

113 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Keith P McCulloughArbor Research Collaborative for Health, Ann Arbor, Michigan; and Departments of keith.mccullough@arborresearch.org.
Hal MorgensternEpidemiology and.
Rajiv SaranEpidemiology and.
William H HermanEpidemiology and.
Bruce M RobinsonArbor Research Collaborative for Health, Ann Arbor, Michigan; and Departments of.
Arbor Research Collaborative for Health · USDiabetes Australia · AUFaculty of Public Health · GBUniversity of Michigan–Ann Arbor · US

Funding

Research BaseP30DK092926 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MARY ELLEN MICHELE HEISLER, ADESUWA B OLOMU · 2011 to 2026
$10.0M
NIDDK NIH HHS P30 DK092926NLM NIH HHS HHSN276201400001C
6 · The paper itself

Abstract

backgroundPopulation rates of obesity, hypertension, diabetes, age, and race can be used in simulation models to develop projections of ESRD incidence and prevalence. Such projections can inform long-range planning for ESRD resources needs.

methodsWe used an open compartmental simulation model to estimate the incidence and prevalence of ESRD in the United States through 2030 on the basis of wide-ranging projections of population obesity and ESRD death rates. Population trends in age, race, hypertension, and diabetes were on the basis of data from the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey and the US Census.

resultsThe increase in ESRD incidence rates within age and race groups has leveled off and/or declined in recent years, but our model indicates that population changes in age and race distribution, obesity and diabetes prevalence, and ESRD survival will result in a 11%-18% increase in the crude incidence rate from 2015 to 2030. This incidence trend along with reductions in ESRD mortality will increase the number of patients with ESRD by 29%-68% during the same period to between 971,000 and 1,259,000 in 2030.

conclusionsThe burden of ESRD will increase in the United States population through 2030 due to demographic, clinical, and lifestyle shifts in the population and improvements in RRT. Planning for ESRD resource allocation should allow for substantial continued growth in the population of patients with ESRD. Future interventions should be directed to preventing the progression of CKD to kidney failure.

Indexed as

Cause of DeathAgedAged, 80 and overComorbidityDiabetes MellitusFemaleHumansHypertensionIncidenceKidney Failure, ChronicMaleMiddle AgedModels, StatisticalObesityPredictive Value of TestsPrevalencecomputer simulationdemographic trendsend stage kidney diseaseUnited States Renal Data System

Identifiers

PMID30559143
PMCPMC6317596
OpenAlexW2905034532

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.